anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Outcome studies have shown that several forms of psychotherapy are effective for depression, but questions about how, why, and when these treatments work remain. The proposed study answers the call for innovative research designs that allow for more intensive, individualized data collection that can address complex questions about the dynamic nature of treatment-related change. In this R21 application, we propose a proof-of-concept study using an innovative application of experience sampling methodology (ESM) that combines the idiographic advantages of single-subject research with the statistical advantages associated with larger samples and multilevel analyses. ESM involves sampling aspects of behavior occurring in the participant's everyday environment, thereby enhancing ecological validity and reducing retrospective bias. Thirtyfour adults with primary major depressive disorder will be randomly assigned to 16 weeks of either selfsystem therapy (SST), a new short-term, empirically-supported psychotherapy for depression that targets deficits in incentive motivation and goal pursuit, or treatment-as-usual (TAU). Participants will complete a battery of individual difference and diagnostic measures at pretreatment. One week of intensive ESM will be collected at both pre- and post-treatment, during which participants will be signaled at random times during each day to answer questions about current functioning in several domains (e.g., affect, cognition, and goal pursuit) delivered via a phone-based interactive voice response (IVR) system. Throughout the 16 weeks of treatment, participants will complete similar IVR assessments on two randomly-selected days per week. The proposed study will test three main hypotheses. (1) Patients in SST will show greater increases in engagement with promotion goals and activities as well as greater increases in goal-related daily experiences of positive affect over the course of treatment compared to patients in TAU. (2) Patients in SST will show greater decreases in engagement with prevention goals and activities as well as greater decreases in goal- related daily experiences of negative affect over the course of treatment compared to patients in TAU. (3) Within the SST condition, a history of failure to pursue or achieve promotion goals and individual differences in chronic regulatory orientation (i.e., strength of orientation toward promotion and prevention goals) will moderate the effects of SST on changes in depressive symptoms and on daily experiences of promotion goal engagement. The proposed research will have a significant impact on an important public health problem and will expand our knowledge of how psychotherapy for depression works. The data to be obtained from this study will provide a sound empirical and theoretical framework for largerscale programmatic research on the nature of treatment-induced change processes in patients with depression.
This research project is designed to study the medication ephedrine, when it is given as a routine part of the anesthesia for elective Cesarean section. Ephedrine is a medication that is widely used in labor and in vaginal and operative (Cesarean section) deliveries to help maintain a woman's blood pressure within its normal range, especially after spinal and epidural anesthesia has been administered. The purpose of this study is to determine if ephedrine, when given intramuscularly (\<IM\> as a shot in the muscle), at the time of spinal anesthesia administration, can help to decrease the incidence of nausea and vomiting subjects experience during and after a Cesarean section. This study will compare women who receive ephedrine to a similar group of women who receive a normal saline placebo. In addition to looking at the difference in the incidence of nausea and vomiting perioperatively, this study will also evaluate if the administration of IM ephedrine helps the baby to receive more blood from the placenta after anesthesia has been administered to the mother. This will be evaluated by performing a simple blood test, drawn from the umbilical cord, after the baby is born.
Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) for 26 weeks followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
A system and method for connecting all health facilities is described by giving each patient, health profession and health facility at least one unique universal predefined permanent ID e.g., face ID, fingerprint, retina pattern . . . etc.. Patient medical history and data of patients, related health professions and related health facilities are taken and saved on a database, then all data related to that particular patient can be viewed, some health professions can modify that data. Moreover, there is a data synchronizer which helps in the connection between different health platforms users and helps in synchronizing data from other health-related platforms, also robotic surgeries can be performed remotely, by artificial intelligence, or by artificial intelligence assistance, and there are lots of other artificial intelligence applications.
Described is a system and method for generating an action plan for diagnosis and treatment of a patient. In particular, a historical database is complied which includes a plurality of records. Each record includes a personal profile and diagnosis data for a person. A plurality of characterizations and corresponding weighting coefficients are derived based on the records in the historical database. Pre-diagnostic patient profile data for a selected patient is obtained for the selected patient. One or more computing modules generate output data for the selected patient as a function of (i) the pre-diagnostic patient profile data, along with the physician's modifications, if any and (ii) the plurality of characterizations and corresponding weighting coefficients. The output data includes at least one of a diagnostic action plan, a confirmation action plan, a confirmation patient profile data and a therapeutic action plan.
Dermatological compsn. for resorption of vergetures contains extracts of horsetail (equisetum), alchemilla and climbing ivy (Hedera helix) and is characterised in that the combined extracts are administered as a glycolic soln. esp. an aqs. glycolic soln. Horsetail contains silica (up to 70% in ashes) in a colloidal form which can be assimilated, alchemilla has action on placid skin and ivy extract effect muscular and neurotissulo-vascular reactions. Compsn. does not cause allergies.
There is a lack of consensus on the role of inhaled nitric oxide (iNO) therapy and other pulmonary vasodilators for the treatment of severe pulmonary hypertension (PH) in premature newborns (\<34 weeks gestation). However, a proper randomized, controlled trial of iNO in premature newborns with severe PH has not been completed. Some practices embrace the American Academy of Pediatrics (AAP) statement that there is no condition for which iNO should be used in the premature newborn, and others selectively treat premature infants with inhaled nitric oxide (iNO) who suffer life threatening hypoxemia due to suprasystemic PH and right-to-left veno-arterial admixture across the arterial duct and/or oval foramen. The number of neonatal intensive care units (NICUs) adopting each of these approaches is currently unknown, but it is possible that the former group is increasing due to administrative pressure to reduce uncompensated off-label iNO use. A prospective registry collection of treatment strategies and outcomes for this subset of premature newborns will help define current treatment strategies and yield important information about safety and efficacy of the different approaches to management, and would inform the debate more effectively than a series of iNO treated infants alone. Data collected includes maternal age, race/ethnicity, pregnancy and delivery complications, prenatal medications, infant characteristics such as Apgar scores, birthweight, congenital anomalies, respiratory status, pharmacologic therapy used for PH and its side effects, and blood gas data. Up to 100 sites in North America will be invited to monitor for appropriate cases.
The invention discloses a recombinant baculovirus expressing heat-resistant HN protein of newcastle disease virus, a preparation method and application thereof. The virus strain is preserved in China center for type culture Collection, the preservation address is, China, Wuhan university, the preservation number is CCTCC NO: v202044. The preparation method comprises the steps of carrying out point mutation on HN genes of a non-heat-resistant LaSota strain of the Newcastle disease virus, wherein the HN genes comprise G49E, R269S, G293E, R353Q and G494D, inserting the mutated HN genes into a baculovirus genome, and obtaining a recombinant baculovirus rAC-HN-N5 strain through virus rescue. The strain can efficiently express the mutant HN protein. Compared with wild type HN protein of LaSota strain, the heat stability of mutant HN protein is obviously enhanced. The mutant HN protein expressed and purified by the recombinant baculovirus rAC-HN-N5 strain can be used for preparing a Newcastle disease heat-resistant subunit vaccine so as to reduce the dependence of the vaccine on a cold chain and provide a new idea for developing the subunit vaccine with good heat stability.
Cephalexin, USP is a semisynthetic cephalosporin antibiotic intended for oral administration. It is 7-(D-α-Amino-α-phenylacetamido)-3-methyl-3-cephem-4-carboxylic acid monohydrate. Cephalexin has the molecular formula C16H17N3O4S•H2O and the molecular weight is 365.41.

Cephalexin has the following structural formula

The nucleus of cephalexin is related to that of other cephalosporin antibiotics. The compound is a zwitterion; i.e., the molecule contains both a basic and an acidic group. The isoelectric point of cephalexin in water is approximately 4.5 to 5.

The crystalline form of cephalexin which is available is a monohydrate. It is a white crystalline solid having a bitter taste. Solubility in water is low at room temperature; 1 or 2 mg/mL may be dissolved readily, but higher concentrations are obtained with increasing difficulty.

The cephalosporins differ from penicillins in the structure of the bicyclic ring system. Cephalexin has a D-phenylglycyl group as substituent at the 7-amino position and an unsubstituted methyl group at the 3-position.

Each capsule contains cephalexin monohydrate equivalent to 250 mg or 500 mg of cephalexin. The capsules also contain anhydrous lactose, gelatin, magnesium stearate, talc and titanium dioxide. The capsules are imprinted with edible ink containing black iron oxide.
The pharmacodynamic response of niraparib has not been characterized.

Hypertension and Cardiovascular Effects

Niraparib has the potential to cause effects on pulse rate and blood pressure in patients receiving the recommended dose, which may be related to pharmacological inhibition of the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT) [see Nonclinical Toxicology (13.2)].

In the PRIMA study, mean pulse rate and blood pressure increased over baseline in the niraparib arm relative to the placebo arm at most on-study assessments. Mean greatest increases from baseline in pulse rate on treatment were 22.4 and 14.0 beats/min in the niraparib and placebo arms, respectively. Mean greatest increases from baseline in systolic blood pressure on treatment were 24.4 and 19.6 mmHg in the niraparib and placebo arms, respectively. Mean greatest increases from baseline in diastolic blood pressure on treatment were 15.9 and 13.9 mmHg in the niraparib and placebo arms, respectively.

In the NOVA study, mean pulse rate and blood pressure increased over baseline in the niraparib arm relative to the placebo arm at all on-study assessments. Mean greatest increases from baseline in pulse rate on treatment were 24.1 and 15.8 beats/min in the niraparib and placebo arms, respectively. Mean greatest increases from baseline in systolic blood pressure on treatment were 24.5 and 18.3 mmHg in the niraparib and placebo arms, respectively. Mean greatest increases from baseline in diastolic blood pressure on treatment were 16.5 and 11.6 mmHg in the niraparib and placebo arms, respectively.

Cardiac Electrophysiology

The potential for QTc prolongation with niraparib was evaluated in a randomized, placebo‑controlled trial in patients with cancer (367 patients on niraparib and 179 patients on placebo). No large changes in the mean QTc interval (>20 ms) were detected in the trial following the treatment of niraparib 300 mg once daily.
PURPOSE:To obtain a low-toxic cariostatic agent effective in remarkably inhibiting the growth of Streptococcus mutans which is a main cariogenic bacterium and usable in the form of a dental antibacterial agent, mouth wash, etc., by using a pyrrolidine derivative as an active component. CONSTITUTION:The objective agent contains a pyrrolidine derivative of formula (A is -CH2- or -O-; n is 8-18) as an active component. The compound of formula is e.g. hexadecanoyl-pyrrolidine, tetradecyl-pyrrolidine and its hydrochloride, hexadecyl-pyrrolidine and its hydrochloride or octadecyl-pyrrolidine. It can be produced e.g. by acylating pyrrolidine with an acid chloride and the alkyl derivative of the compound can be produced by reducing the acyl derivative with a conventional reducing agent such as lithium aluminum hydride. It can be used in various forms of conventional agent such as mouth wash or cleaning agent for oral mucosa.
We hypothesize that a non-invasive 30-minute test, requiring a subject to complete questionnaires and watch images on a TV screen, will yield information relevant to both diagnosis and prognosis of neurological state. To clarify, these tests will not produce information that would involve a diagnostic finding for the participants. We will measure eye movements under a range of visual conditions, including saccades, fixations, smooth pursuit, scan paths and optico-kinetic nystagmus

After receiving proper introduction and signing the proper consent forms, the subject will receive instructions to carry out cognitive assessments and answer verbal questionnaires. The subject will also undergo eye tracking. In order to validate the data collected by our eye-trackers, we may ask the subject to complete a non-invasive vision assessment and a breathalyzer assessment. Due to the nature of the breathalyzer assessment, we have decided not to administer the breathalyzer assessment to subjects who are under the age of 21 and/or pregnant. We also refuse to disclose the results of the breathalyzer assessment to the subject since the data will be collected only for research purposes. Subjects' eye movements will be tracked binocularly at a fixed distance from a computer monitor over a brief time period. The visual stimuli will be video clips appropriate for a general or pediatric audience. If at any point the subject becomes uncomfortable, the procedure will be aborted and can be resumed at a later time.
A placebo beverage is going to be prepared using noncaloric berry-flavored sweetener consisting of sucralose candy drops, which will be crushed and dissolved in 150 ml of warm water. Prior to use, solutions are going to be aliquoted for mouth rinse and warmed at room temperature. Then, it will be served to each athlete on individual bottles in a total dose of 75 ml before exercise and 75 ml during exercise.
Max dose Tetrodotoxin injectable (1 ml volume), once a day in the morning for four consecutive days and Placebo for injection (1 ml volume), once a day in the afternoon for four consecutive days. Total of 4 treatment days.
Our previous study has documented that knee IA PRP injection combined with PRP injection to the pes anserine complex offered better treatment effectiveness as compared with IA PRP alone. In this two-year study, patients with moderate to severe degrees of knee OA will be recruited and divided into 3 groups. The high frequency PRP injection method will be applied (weekly PRP injections for a total of 3 weeks). Group 1 will receive knee IA PRP injections only. Group 2 will receive simultaneous knee IA PRP injections and PRP injections to the pes anserine complex. Group 3 will receive simultaneous knee IA PRP injections and PRP injections to the pes anserine complex, as well as to the genicular nerve blocks using 5% dextrose solution. We hypothesize that patients in group 3 will have better treatment outcomes. The effectiveness will be examined using proteomics, isokinetic measurements and functional scale evaluations. Upon the completion of this study, we will be able to gather adequate scientific evidences as to which injection approach and what PRP injection frequency is a better option in treating patients with moderate to severe degrees of knee OA.
Up to 3 dose levels of hP1A8 will be tested with a Dose Level -1 in the event of toxicity. The MTD will be identified using the standard 3+3 design. Upon determination of the MTD, additional patients will be enrolled as part of an expansion cohort.
Appts. for a security telephone device connected or connectable to a supervision unit for administering one or more reception units, by means of a telecom subscription link. In addition to the usual security telephone function, the appts. has a function for supervising the administration of medicine prescribed to the subscriber, this function being carried out by means of timing units that can be activated at respective intervals in order to act as a reminder function which informs the subscriber that it is time to take the medication. These timing devices can be adjusted and installed from the telecom or supervision system, the system sending out real time information governed by a highly-accurate real-time clock in the system, that is received by the reception unit(s) from the medical institution. The appts. provides the subscriber with a means of confirming that the information has been received and in the case of non-receival of this confirmation, an alarm will be signalled at the supervision unit.
Patients receive testosterone IM on day 1 of each cycle. Cycles repeat every 28 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also continue to receive standard of care leuprolide acetate SC per their standard schedule. Patients undergo CT scan, bone scan and may undergo MRI and tumor biopsy throughout the study.
As a natural preservative, nisin is widely used in the food industry, while its application in biomedicine is limited due to its susceptibility to interference from external conditions. In this study, a nanoparticle-hydrogel composite system was designed to encapsulate and release nisin. Nisin nanoparticles were identified with a smooth, spherical visual morphology, particle size of 122.72 ± 4.88 nm, polydispersity coefficient of 0.473 ± 0.063, and zeta potential of 23.89 ± 0.37 mV. Based on the sample state and critical properties, three temperature-sensitive hydrogels based on chitosan were ultimately chosen with a rapid gelation time of 112 s, outstanding reticular structure, and optimal swelling ratio of 239.05 ± 7.15%. The composite system exhibited the same antibacterial properties as nisin, demonstrated by the composite system's inhibition zone diameter of 17.06 ± 0.83 mm, compared to 20.20 ± 0.58 mm for nisin, which was attributed to the prolonged release effect of the hydrogel at the appropriate temperature. The composite system also demonstrated good biocompatibility and safety, making it suitable for application as short-term wound dressings in biomedicine due to its low hemolysis rate of less than 2%. In summary, our nanoparticle-based hydrogel composite system offers a novel application form of nisin while ensuring its stability, thereby deepening and broadening the employment of nisin.
The Brazilian Cerrado biome is rich in plant biodiversity, with fruits that have unique sensory characteristics and high nutritional quality. Among the various fruits, baru (Dipteryx alata Vog.) has attracted the attention of researchers because of its high lipid, protein, carbohydrate, fiber, and micronutrient (minerals and vitamins) contents. The present study evaluated the effects of regular consumption of baru almonds for over 60 days on the biochemical and anthropometric profiles and fecal microbiota of obese individuals. A pilot study was conducted on 15 individuals with obesity who were instructed to consume a 20-gram portion of baru almonds throughout the day. The body composition was assessed using anthropometric measurements. Blood pressure, glucose levels, lipid profile, serum insulin and iron contents, and fecal microbiota composition were determined at baseline (day 0) and after 60 days. Baru almond consumption contributed to changes in biochemical parameters, improved HDL cholesterol levels, and reduced total and LDL cholesterol levels. Some positive changes in the microbiota composition after consuming baru almonds include a decrease in the Faecalibacterium family and an increase in the Provotella genus. Therefore, ingesting baru almonds can modulate gut microbiota of individuals with obesity.
Ivermectin (IVM) is a broad spectrum antiparasitic drug. Recent research indicates that IVM could potentially be used in malaria vector control.

The present study assesses the pharmacokinetic profile of IVM in healthy human volunteers and aims to create a physiologically-based pharmacokinetic model. This model will be used to characterize enterohepatic circulation, serve as a basis for drug-drug and drug-disease-state interaction studies, and simulations of IVM disposition in different populations, with special regard given to adolescents and children. With this, safety in individual administrations can be increased, and mass drug administration programs, e.g. oral IVM as malaria vector control, be simulated and planned to maximize the share of a population that can be included. Capillary blood concentration profiles will also be determined to assess the amount of IVM delivered to mosquitos in malaria vector control programs. Furthermore, this study will validate dried blood spot analytics of IVM which will allow easier procurement of pharmacokinetics (PK) data in the field.
Standard therapy group will receive basal-bolus insulin starting at a dose of 0.5 units/kg/day; given half as insulin glargine and half as insulin aspart. In addition, the standard therapy group will receive the correctional sliding scale insulin therapy before each meal and bedtime.
Pharmaceutical preparation in the form of a liquid dosage, preferably a soothing agent against cough, comprises a combination of at least two mucilaginous drugs, preferably a combination of iceland moss (Lichen islandicus) and at least a further mucilaginous drug, preferably together with a harmless, preferably pharmacologically-harmless carrier. An independent claim is included for a combination of at least two mucilaginous drugs, preferably combination of iceland moss (Lichen islandicus) and at least a further mucilaginous drug, preferably from marsh mallow (Althaea officinalis L.), ribwort (Plantago lanceolata L.), malves (Malva sylvestris L. and M. neglecta Wallr.), fenugreek (Trigonella foenum graecum L.), salep and quince (Cydonia oblonga Mill.), preferably in the form of their respective extracts, optionally together with at least a zinc compound, preferably for the use of the preventive and/or therapeutic treatment of and/or for production of a medicament for the preventive and/or therapeutic treatment of coughs and cough stimulus, preferably dry cough with throat irritation; mucous membrane irritation and lesions in the mouth and throat area; drying of the mucous membranes within the mouth and throat area; hoarseness; bronchial catarrhs and bronchial asthma and bronchial asthma. ACTIVITY : Antitussive; Antiinflammatory; Antiasthmatic. MECHANISM OF ACTION : None given.